Heidi Schilter

List of Publications by Citations

9 papers	196 citations	7 h-index	9 g-index
9 ext. papers	269 ext. citations	6.2 avg, IF	2.63 L-index

#	Paper	IF	Citations
9	The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis. *Journal of Cellular and Molecular Medicine*, **2019**, 23, 1759-1770	5.6	49
8	PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo. *Journal of Pharmacology and Experimental Therapeutics*, **2013**, 347, 365-74	4.7	37
7	Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration. *Respiratory Research*, **2015**, 16, 42	7.3	36
6	Therapeutic targets in lung tissue remodelling and fibrosis. *Pharmacology & Therapeutics*, **2021**, 225, 107839	13.9	25
5	Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3. *Journal of Medicinal Chemistry*, **2019**, 62, 9874-9889	8.3	19
4	Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model. *American Journal of Physiology - Renal Physiology*, **2014**, 307, F908-16	4.3	15
3	The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF-β1 pathway in human lung fibroblasts. *Immunology Letters*, **2015**, 165, 90-101	4.1	9
2	Semicarbazide-sensitive amine oxidase inhibition ameliorates albuminuria and glomerulosclerosis but does not improve tubulointerstitial fibrosis in diabetic nephropathy. *PLoS ONE*, **2020**, 15, e0234617	3.7	3
1	An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategies. *Clinical and Translational Medicine*, **2021**, 11, e572	5.7	3